Posted on

Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccine as an active booster immunization against tetanus, diphtheria and pertussis

General Track - Cycle 3 | Vaccines

HTA Council Final Recommendation (as of 26 May 2025)

The HTA Council positively recommends the government financing of Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccine for the following populations:

  1. Pregnant women, contingent on the availability of funds, and;
  2. Grade 1 and Grade 7 students in a phased implementation (by region), contingent on: 
    • the availability of funds; AND
    • The achievement of ≥90% primary series vaccination coverage for the region. (See below for more details)

Relevant Information

  • Dosage Strength
    • Each dose (0.5 mL) contains: Diphtheria toxoid (2.5 Lf); Tetanus toxoid (5.0 Lf); Pertussis toxoid (8µg); Filamentous hemagglutinin (FHA) (8µg); Pertactin (PRN or 69 kDa OMP) (2.5µg)
    • Each dose (0.5 mL) contains: Diphtheria Toxoid Adsorbed (2 Lf); Tetanus Toxoid Adsorbed (5 Lf); Component Acellular Pertussis: [Pertussis Toxoid (PT) (2.5µg); Filamentous Haemagglutinin Adsorbed (FHA) (5µg); Fimbriae Types 2 and 2 Adsorbed (5µg); Pertactin (PRN) (3µg)
  • Dosage Forms:
    • Suspension for Injection (IM)
    • Solution for Injection (IM)
  • Status: with Final HTA Council Recommendation
  • Topic Assignment: Internal Assessment
  • Policy Question: Should Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccine as an active booster immunization against tetanus, diphtheria and pertussis be funded by the government?
  • Secretary of Health Decision:  Approved for inclusion in the Philippine National Formulary

Evidence and Relevant Documents

Back to Assessments Page